No connection

Search Results

POM

BEARISH
$0.38 Live
Pomdoctor Limited · NASDAQ
$0.19 52W Range $6.43

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 17, 2026
Market cap
$45.43M
P/E
N/A
ROE
N/A
Profit margin
-40.6%
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
Pomdoctor Limited exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a catastrophic liquidity profile. With a Current Ratio of 0.17 and a negative Price-to-Book ratio (-0.04), the company is effectively insolvent and unable to meet its short-term obligations. Despite a modest 16.2% revenue growth, the stock has collapsed by over 90% across all major timeframes, signaling a complete loss of investor confidence and high bankruptcy risk.

Key Strengths

Positive year-over-year revenue growth of 16.20%
Extremely low Price-to-Sales ratio (0.12)
Positive gross margin (14.08%)
Operating margin is significantly less negative than net profit margin
Recent 1-week short-term price bounce (+17.2%)

Key Risks

Severe liquidity crisis with a Current Ratio of 0.17
Negative equity as indicated by the -0.04 Price/Book ratio
Massive price devaluation (-90.5% over 1 year)
Poor profitability with a -40.59% profit margin
Significant underperformance relative to healthcare sector growth averages

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
10
Weak
Value
10
Future
25
Past
5
Health
8
Dividend
0
AI Verdict
High Risk / Distressed
Key drivers: Insolvency risk (Negative P/B), Liquidity failure (Current Ratio 0.17), Chronic price collapse, Weak Piotroski F-Score
Confidence
95%
Value
10/100

P/B of -0.04 suggests the company's liabilities exceed its assets.

Positives
  • Low P/S ratio
Watchpoints
  • Negative Book Value
  • No Graham Number available due to lack of earnings/equity
Future
25/100

Revenue growth is insufficient to offset operational losses.

Positives
  • Modest revenue growth
Watchpoints
  • Growth is far below sector average (16.2% vs 124.5%)
  • Negative profit margins
Past
5/100

Consistent long-term value destruction.

Positives
No standout positives identified.
Watchpoints
  • 90.5% decline over 1, 3, and 5 years
  • Extreme volatility
Health
8/100

Critical failure in liquidity and operational efficiency.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score 3/9
  • Quick Ratio 0.09
  • ROA -32.56%
Dividend
0/100

Company is in no position to return capital.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.38

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for POM and closest competitors.

Updated 2026-04-16
POM
Pomdoctor Limited
Primary
5Y
-90.5%
3Y
-90.5%
1Y
-90.5%
6M
-91.4%
1M
-7.3%
1W
+17.2%
ONM
OneMedNet Corporation
Peer
5Y
-91.1%
3Y
-91.8%
1Y
+65.5%
6M
-68.2%
1M
+9.7%
1W
+2.6%
IMM
Immutep Limited
Peer
5Y
-91.1%
3Y
-80.6%
1Y
-78.0%
6M
-84.6%
1M
-88.8%
1W
-13.9%
ALG
Aligos Therapeutics, Inc.
Peer
5Y
-98.8%
3Y
-77.7%
1Y
-26.4%
6M
-25.8%
1M
+1.5%
1W
+8.4%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
N/A
PEG Ratio
N/A
P/B Ratio
-0.04
P/S Ratio
0.12
EV/Revenue
6.18
EV/EBITDA
-87.43
Market Cap
$45.43M

Profitability

Profit margins and return metrics

Profit Margin -40.59%
Operating Margin -6.54%
Gross Margin 14.08%
ROE N/A
ROA -32.56%

Growth

Revenue and earnings growth rates

Revenue Growth +16.2%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.17
Weak
Quick Ratio
0.09
Poor
Cash/Share
$0.91

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2024

Total Assets
$0.0B
Liabilities
$2.1B
Equity
$-2.3B
Debt/Equity
-0.95x

Healthcare Sector Comparison

Comparing POM against 393 companies in the Healthcare sector (24 bullish, 129 neutral, 240 bearish)
Profit Margin
-40.59%
This Stock
vs
-12.47%
Sector Avg
+225.5% (Superior)
Revenue Growth
16.2%
This Stock
vs
124.21%
Sector Avg
-87.0% (Slower)
Current Ratio
0.17
This Stock
vs
4.56
Sector Avg
-96.2% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning POM from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile